Listed

CVS HEALTH Corp: Form 10-Q for the period ended Sep 30, 2013

Filed with the SEC on Nov 5, 2013 and accepted by EDGAR at Nov 5, 2013, 16:08 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-07-01 to 2013-09-30$31.97bnus-gaap:Revenues
Revenue9 months2013-01-01 to 2013-09-30$93.98bnus-gaap:Revenues
Cost of revenue3 months2013-07-01 to 2013-09-30$25.93bnus-gaap:CostOfRevenue
Cost of revenue9 months2013-01-01 to 2013-09-30$76.53bnus-gaap:CostOfRevenue
Gross profit3 months2013-07-01 to 2013-09-30$6.04bnus-gaap:GrossProfit
Gross profit9 months2013-01-01 to 2013-09-30$17.45bnus-gaap:GrossProfit
Operating income3 months2013-07-01 to 2013-09-30$2.16bnus-gaap:OperatingIncomeLoss
Operating income9 months2013-01-01 to 2013-09-30$5.83bnus-gaap:OperatingIncomeLoss
Interest expense3 months2013-07-01 to 2013-09-30$125.0mus-gaap:InterestExpense
Interest expense9 months2013-01-01 to 2013-09-30$379.0mus-gaap:InterestExpense
Income tax3 months2013-07-01 to 2013-09-30$779.0mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2013-01-01 to 2013-09-30$2.12bnus-gaap:IncomeTaxExpenseBenefit
Net income3 months2013-07-01 to 2013-09-30$1.25bnus-gaap:ProfitLoss
Net income9 months2013-01-01 to 2013-09-30$3.33bnus-gaap:ProfitLoss
Diluted EPS3 months2013-07-01 to 2013-09-30$1.02us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2013-01-01 to 2013-09-30$2.70us-gaap:EarningsPerShareDiluted
Basic EPS3 months2013-07-01 to 2013-09-30$1.03us-gaap:EarningsPerShareBasic
Basic EPS9 months2013-01-01 to 2013-09-30$2.72us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2013-07-01 to 2013-09-301,226,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2013-01-01 to 2013-09-301,234,000,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2013-01-01 to 2013-09-30$4.25bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2013-01-01 to 2013-09-30$1.33bnus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2013-01-01 to 2013-09-30$829.0mus-gaap:PaymentsOfDividends
Share repurchases9 months2013-01-01 to 2013-09-30$2.27bnus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2013-09-30$1.50bnus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-09-30$21.43bnus-gaap:AssetsCurrent
Total assetsAt period end2013-09-30$67.81bnus-gaap:Assets
Current liabilitiesAt period end2013-09-30$15.10bnus-gaap:LiabilitiesCurrent
Long-term debtAt period end2013-09-30$8.82bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2013-09-30$572.0mus-gaap:LongTermDebtCurrent
Short-term borrowingsAt period end2013-09-30$814.0mus-gaap:ShortTermBorrowings
Shareholders' equityAt period end2013-09-30$38.53bnus-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Source: SEC EDGAR, the filing index for accession 0000064803-13-000027. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.